Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACOG Alpha Cognition	$8.10 -1.9%	$9.53	$3.75 ▼ $11.54	$133.49M	2.72	69,551 shs	58,819 shs
COEP Coeptis Therapeutics	$13.46 +0.2%	$10.14	$2.31 ▼ $14.70	$64.74M	-0.59	52,938 shs	43,507 shs
LXEO Lexeo Therapeutics	$4.90 +2.5%	$4.38	$1.45 ▼ $12.37	$258.13M	1.36	392,470 shs	519,073 shs
MEIP MEI Pharma	$4.97 +7.6%	$4.06	$1.46 ▼ $9.00	$149.54M	0.37	578,303 shs	507,341 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACOG Alpha Cognition	+3.38%	+3.25%	-15.71%	-9.63%	+825,999,900.00%
COEP Coeptis Therapeutics	-1.32%	+16.99%	+23.10%	+29.01%	+216.75%
LXEO Lexeo Therapeutics	-0.42%	-0.21%	+22.88%	+69.50%	-62.33%
MEIP MEI Pharma	+0.65%	-5.71%	-32.65%	+114.39%	+47.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACOG Alpha Cognition	2.1916 of 5 stars	3.5	0.0	0.0	2.0	2.5	0.0
COEP Coeptis Therapeutics	0.7339 of 5 stars	0.0	3.0	0.0	2.7	1.7	0.0
LXEO Lexeo Therapeutics	2.4216 of 5 stars	3.5	1.0	0.0	2.1	2.5	0.6
MEIP MEI Pharma	1.5017 of 5 stars	0.0	2.0	4.2	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACOG Alpha Cognition	3.00	Buy	$20.00	146.91% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
LXEO Lexeo Therapeutics	3.00	Buy	$15.33	212.93% Upside
MEIP MEI Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest COEP, ACOG, MEIP, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $15.00
8/15/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $9.00
7/31/2025	LXEO Lexeo Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	$2.59 per share	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.47 per share	N/A
LXEO Lexeo Therapeutics	$650K	407.08	N/A	N/A	$2.56 per share	1.91
MEIP MEI Pharma	$65.30M	2.46	$6.45 per share	0.77	$4.96 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACOG Alpha Cognition	-$14.64M	-$1.60	N/A	∞	N/A	N/A	-80.16%	-60.95%	N/A
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-201.73%	-108.46%	N/A
LXEO Lexeo Therapeutics	-$98.33M	-$3.26	N/A	N/A	N/A	N/A	-94.65%	-73.36%	N/A
MEIP MEI Pharma	$17.78M	-$4.75	N/A	N/A	N/A	N/A	-77.00%	-64.79%	9/18/2025 (Estimated)

Latest COEP, ACOG, MEIP, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACOG Alpha Cognition	-$0.46	-$0.65	-$0.19	-$0.65	$2.32 million	$1.66 million
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/14/2025	Q2 2025	LXEO Lexeo Therapeutics	-$0.64	-$0.60	+$0.04	-$0.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACOG Alpha Cognition	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
MEIP MEI Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACOG Alpha Cognition	N/A	17.14	16.83
COEP Coeptis Therapeutics	0.02	0.83	0.82
LXEO Lexeo Therapeutics	N/A	4.43	3.42
MEIP MEI Pharma	N/A	16.78	16.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACOG Alpha Cognition	N/A
COEP Coeptis Therapeutics	13.88%
LXEO Lexeo Therapeutics	60.67%
MEIP MEI Pharma	52.38%

Insider Ownership

Company	Insider Ownership
ACOG Alpha Cognition	14.00%
COEP Coeptis Therapeutics	24.25%
LXEO Lexeo Therapeutics	5.30%
MEIP MEI Pharma	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACOG Alpha Cognition	N/A	16.16 million	13.90 million	N/A
COEP Coeptis Therapeutics	2	4.82 million	2.66 million	Not Optionable
LXEO Lexeo Therapeutics	58	54.00 million	31.44 million	Not Optionable
MEIP MEI Pharma	100	32.37 million	31.36 million	Optionable

COEP, ACOG, MEIP, and LXEO Headlines

Recent News About These Companies

MEI Pharma, Inc. (NASDAQ:MEIP) Short Interest Up 12,046.9% in July

August 16, 2025 | marketbeat.com

Short Interest in MEI Pharma, Inc. (NASDAQ:MEIP) Expands By 12,046.9%

August 16, 2025 | americanbankingnews.com

MEI Pharma Welcomes New Board Member Joshua Riezman

August 11, 2025 | theglobeandmail.com

MEI Pharma files to sell 25.3M shares of common stock for holders

August 7, 2025 | msn.com

MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

August 5, 2025 | joplinglobe.comJ

MEI Pharma’s Strategic Shift with Litecoin Treasury

July 25, 2025 | theglobeandmail.com

MEI Pharma's Bold Bet: First Public Company to Go All-In on Litecoin Treasury

July 25, 2025 | econotimes.com

Public Shell Firms Ramping Up Altcoin Buys Draws Skepticism: FT

July 25, 2025 | coindesk.com

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

July 24, 2025 | thenewswire.comT

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

July 22, 2025 | businesswire.com

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

July 20, 2025 | msn.com

MEI Pharma Unveils $100M Litecoin Treasury Plan

July 19, 2025 | livebitcoinnews.comL

GSR leads $100M private placement into Nasdaq-listed MEI Pharma to launch Litecoin treasury

July 18, 2025 | coinjournal.net

MEI Pharma Shares Surge After Unveiling $100 Million Litecoin Treasury Plan

July 18, 2025 | msn.com

MEI Pharma Stock Surges on $100M Private Placement, Litecoin Treasury Strategy

July 18, 2025 | marketwatch.com

MEI Pharma Commits $100M to Litecoin Treasury Strategy: Can LTC Price 10x?

July 18, 2025 | blockonomi.com

Nasdaq-listed MEI Pharma launches $100M Litecoin treasury plan, stock rockets 50%

July 18, 2025 | cryptobriefing.comC

Litecoin Price Forecast: LTC reclaims $100 as NASDAQ-listed MEI Pharma unveils $100 million treasury

July 18, 2025 | fxstreet.com

Big Pharma joins crypto with a private placement for $100 Million Litecoin Treasury Strategy

July 18, 2025 | msn.com

MEI Pharma Announces $100M Placement To Initiate Litecoin Treasury Strategy: Retail Cheers Charlie Lee’s Addition To Company Board

July 18, 2025 | msn.com

Why Is MEI Pharma Stock Soaring On Friday?

July 18, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COEP, ACOG, MEIP, and LXEO Company Descriptions

Alpha Cognition NASDAQ:ACOG

$8.10 -0.16 (-1.94%)

As of 04:00 PM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Coeptis Therapeutics NASDAQ:COEP

$13.46 +0.03 (+0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$13.50 +0.04 (+0.30%)

As of 07:19 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$4.90 +0.12 (+2.51%)

Closing price 04:00 PM Eastern

Extended Trading

$4.90 +0.00 (+0.02%)

As of 07:56 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

MEI Pharma NASDAQ:MEIP

$4.97 +0.35 (+7.58%)

Closing price 04:00 PM Eastern

Extended Trading

$5.00 +0.03 (+0.50%)

As of 07:54 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time